INTEGRAMED AMERICA INC Form 10-Q/A December 27, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q/A
Amendment No. 1

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2006

OR

[] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 0-20260

IntegraMed America, Inc. (Exact name of Registrant as specified in its charter)

Delaware 06-1150326

(State or other jurisdiction of incorporation or organization)

(State or other jurisdiction of (I.R.S. employer identification no.)

Two Manhattanville Road

Purchase, New York
(Address of principal executive offices)

10577 (Zip code)

(914) 253-8000 (Registrant's telephone number, including area code)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes _____ No $_X_$

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes $___$ No $__X_$

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes $_X_$ No $__$

Indicate by check mark if disclosure of delinquent filer pursuant to Item

405 of Regulation S-K (17 CFR 229.405) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K [].

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one): Large Accelerated Filer Accelerated Filer Non-Accelerated Filer X .

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes _____ No __X__

The aggregate number of shares of the Registrant's Common Stock, \$.01 par value, outstanding on April 28, 2006 was 5,127,300.

INTEGRAMED AMERICA, INC. FORM 10-Q/A

TABLE OF CONTENTS

PAGE PART I - FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) Consolidated Balance Sheets at March 31, 2006 and December 31, 2005...... 4 Consolidated Statements of Income for the three-month periods ended March 31, 2006 and 2005 5 Consolidated Statements of Shareholders' Equity for the three-month period ended March 31, 2006...... 6 Consolidated Statements of Cash Flows for the three-month periods ended March 31, 2006 and 2005 7 Notes to Consolidated Financial Statements8-11 Management's Discussion and Analysis of Financial Condition Item 3. Quantitative and Qualitative Disclosures About Market Risk.....18 PART II - OTHER INFORMATION

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 3.	Defaults upon Senior Securities	19
Item 4.	Submission of Matters to a Vote of Security Holders	19
Item 5.	Other Information	19
Item 6.	Exhibits	19
SIGNATURES		20
	NS PURSUANT TO 18 U.S.C. ss.1350, AS ADOPTED PURSUANT TO SECTION NES-OXLEY ACT OF 2002 EXHI	
	NS PURSUANT TO 18 U.S.C ss.1350, AS ADOPTED PURSUANT TO SECTION NES-OXLEY ACT OF 2002EXHI	

2

Explanatory Note

During October 2006, we provided notification that our financial statements for 2005 and the first two quarters of 2006 could not be relied upon, and will be restated due to an accounting error. The restatements will not result in any changes to net income or earnings per share for any period, but will, as of March 31, 2006, have the effect of increasing Intangible assets by \$1,934,000, decreasing deferred tax assets by \$784,000 and increasing deferred tax liabilities by \$1,150,000, all non-cash items.

Except as discussed above, and except as required to reflect the effects of the restatement in this Form 10-Q/A, we have not modified or updated disclosures presented in the original quarterly report on Form 10-Q. Accordingly, this Form 10-Q/A does not reflect events occurring after the filing of our original Form 10-Q or modify or update those disclosures affected by subsequent events, except as specifically referenced herein. Information not affected by the restatement is unchanged and reflects the disclosures made at the time of the original filing of the Form 10-Q. Accordingly, this Form 10-Q/A should be read in conjunction with our periodic filings made with the SEC subsequent to the date of the original filing, including any amendments to those filings, as well as any Current Reports filed on Form 8-K subsequent to the date of the original filing. The following items have been amended as a result of the restatement:

Part 1 - Item 1 - Financial Statements

Part 1 - Item 2 - Management's Discussion and Analysis

Part 1 - Item 4 - Controls and Procedures

In addition, in accordance with applicable SEC rules, this amended Quarterly Report on Form 10-Q/A includes updated certifications from our Chief Executive Officer (CEO) and Chief Financial Officer (CFO).

Please refer to Note 2 to the accompanying Consolidated Financial Statements for additional information on the restatement.

3

PART I -- FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

INTEGRAMED AMERICA, INC. CONSOLIDATED BALANCE SHEETS (all dollars in thousands, except share amounts)

ASSETS

	March 31,
	2006
	(unaudited)
ASSETS	
Current assets:	
Cash and cash equivalents	\$ 19 , 917
Pharmaceutical and other receivables, net	875
Deferred income taxes, net	895
Prepaids and other current assets	4,289
Total current assets	25,976
Fixed assets, net	14,513
Exclusive Service Rights and other intangibles, net	24,014
Other assets	651
Total assets	\$ 65,154 ======
LIABILITIES AND SHAREHOLDERS' EQUITY	
Current liabilities:	
Accounts payable	\$ 623
Accrued liabilities	6,989
Current portion of long-term notes payable and other obligations	1,501
Due to medical practices	3,984
Shared Risk Refund program patient deposits	5,009
Total current liabilities	18,106
Deferred tax liability	1,150
Long-term notes payable and other obligations	8,271
long term noted parable and tener obligations	
Total Liabilities	27,527
Commitments and Contingencies	
Charabaldana! aguitus	
Shareholders' equity: Common Stock, \$.01 par value - 15,000,000 shares authorized; 5,127,300 and 5,102,627 shares issued and	
outstanding in 2006 and 2005, respectively	51

De

Capital in excess of par

Deferred Compensation	(658)	
Treasury stock, at cost - 0 and 105,768 shares in 2006 and 2005, respectively Accumulated deficit	 (11,231)	(
Total shareholders' equity	37,627	
Total liabilities and shareholders' equity	\$ 65,154	\$
		==

See accompanying notes to the consolidated financial statements.

4

INTEGRAMED AMERICA, INC. CONSOLIDATED STATEMENTS OF INCOME (all amounts in thousands, except per share amounts)

	For the three-month period ended March 31,		
	2006	2005	
		dited)	
Revenues, net			
Provider Services	2,658	\$ 25,714 6,249	
Total revenues	30,434	31,963	
Costs of revenues:			
Provider Services costs	25,032	23,019	
Consumer Services costs	1,640	5 , 611	
Total costs of revenues	26 , 672		
Contribution			
Provider Services contribution	2,744	2,695	
Consumer Services contribution	1,018	638	
Total contribution	3,762	3,333	
General and administrative expenses	3,052	2,834	
Interest income	(221)	(100)	
Interest expense	159	97	
Total other expenses	2 , 990		

49,465

Income before income taxes		772 296 		502 188
Net income	\$	476 =====	\$ ==	314
Basic and diluted net earnings per share: Basic earnings per share	\$	0.09	\$	0.07
Diluted earnings per share		0.09		0.06
Weighted average shares - basic	==:	5 , 201	==	4,740
Weighted average shares - diluted	==:	5 , 303	==	5,010

See accompanying notes to the consolidated financial statements.

5

INTEGRAMED AMERICA, INC. CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (all amounts in thousands) (unaudited)

	Common S	Stock Amount	Capital in Excess of Par	Deferred Compensation	Treasury Shares	Stock Amoun
BALANCE AT DECEMBER 31, 2005	5,103	\$ 51	\$49,747	\$(354)	106	\$(937
Restricted Stock Grant	32		400	(400)		
Stock grant amortization				96		J
Options and warrants exercised	108	1	315		10	(121
Stock Option expense			60			
Cancellation of Treasury Stock	(116)) (1)	(1,057)		(116)	1,058
Net income for the quarter ended 03/	31/06					
-						
BALANCE AT MARCH 31, 2006	5 , 127	\$ 51	\$49,465	\$(658)		\$
	=====	====	======	=====	====	=====

See accompanying notes to the consolidated financial statements.

6

INTEGRAMED AMERICA, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (all amounts in thousands)

	For the three-month period ended March 31,			
			2005	5
Cash flows from operating activities:	<u> </u>	7.6		21.4
Net income	\$ 4	76	\$ 3	314
Depreciation and amortization	1,4	21	1,3	318
Deferred income tax provision	2	16	1	127
Stock-based compensation		96		60
Pharmaceutical and other accounts receivable	(3	85)	(2	205)
Prepaids and other current assets	(1,5	21)	(1,8	307)
Other assets Increase (decrease) in liabilities:	(61)	(1	117)
Accounts payable	(2	94)	2	263
Accrued liabilities	(9	94)	-	191)
Due to medical practices	(9	65)	(1, 2	255)
Shared Risk Refund program patient deposits	2	70 	1,0	
Net cash provided by (used in) operating activities	(1,7	41)	(4	148)
Cash flows from investing activities:				
Payment for exclusive FertilityPartners service rights			(3,3	
Purchase of fixed assets and leasehold improvements	(6		(2,0	
Net cash provided by (used in) investing activities	(6	83)	(5,4	103)
Cash flows from financing activities:				
Principal repayments on debt	(3			287)
Principal repayments under capital lease obligations		18)		(16)
Exercise of common stock options and warrants	1	95 	1	187
Net cash provided by (used in) financing activities	(1	80)	(1	116)
Net increase (decrease) in cash and cash equivalents	(2,6	04)	(5,9	967)
Cash and cash equivalents at beginning of period	22,5		11,3	
Cash and cash equivalents at end of period	\$ 19,9	17	\$ 5,3	333
Supplemental Information:				
Interest paid	\$ 2	82	\$ 2	228
Income taxes paid			\$	75

See accompanying notes to the consolidated financial statements.

7

INTEGRAMED AMERICA, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTE 1 -- INTERIM RESULTS:

The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, accordingly, do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying unaudited interim financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position at March 31, 2006, and the results of operations and cash flows for the interim periods presented. Operating results for the interim period are not necessarily indicative of results that may be expected for the year ending December 31, 2006. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in IntegraMed America's Annual Report on Form 10-K for the year ended December 31, 2005.

Certain amounts from our March 31, 2005 presentations have been reclassified to conform with our current 2006 presentation.

NOTE 2 -- RESTATEMENT:

During October 2006, we provided notification that our financial statements for 2005 and the first two quarters of 2006 could not be relied on, and would be restated due to an accounting error. The restatements will not result in any changes to net income or earnings per share for any period.

The restatement was required in order to correct an error regarding the deferred income tax accounting of acquiring the stock of Reproductive Partners, Inc. in January 2005 in accordance with Financial Accounting Standards Board Emerging Issues Taskforce Issue No. 98-11 "Accounting for Acquired Temporary Differences in Certain Purchase Transactions That Are Not Accounted for as Business Combinations". The following table illustrates the impact of the correction:

	Three Months Ended March 31, 2006		Three Months March 31, 2
A:	s Previously Reported	Restated	As Previously Reported
Statement of Operations Summary: Revenues	30,454	30,434	31,983 31

Income before taxes	792	772	522	
Income tax provision	316	296	208	
Net income	476	476	314	
Earnings Per Share	0.07	0.07	0.06	
Balance Sheet Summary: March 31, 2006	64.004	65.454	50.040	
Total Assets	64,004	65 , 154	53 , 942	
Total Liabilities	26 , 377	27 , 527	18 , 938	
Total Stockholders Equity	37 , 627	37 , 627	35,004	

The information related to December 31, 2005 and March 31, 2005 contained in this document has been restated to reflect the correction of the error described above.

8

INTEGRAMED AMERICA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED (unaudited)

NOTE 3 -- COMMON SHARES OUTSTANDING:

All common share numbers reported herein reflect the 30% Stock Split effected in the form of a Dividend declared by the Board of Directors on May 23, 2005 and paid to shareholders on June 22, 2005.

NOTE 4 -- EARNINGS PER SHARE:

The reconciliation of the numerators and denominators of the basic and diluted EPS computations for the three-month periods ended March 31, 2006 and 2005 is as follows (000's omitted, except for per share amounts):

	For the three-month period ended March 31,		
	2006		
Numerator Net Income	\$ 476 =====	\$ 314 =====	
Denominator Weighted average shares outstanding (basic) Effect of dilutive options and warrants	5,201 102	4,740 270	
Weighted average shares and dilutive potential Common shares (diluted)	5,303 =====	5,010 =====	
Basic EPS	\$ 0.09	\$ 0.07	
Diluted EPS	\$ 0.09		

35

For the three-month periods ended March 31, 2006 and 2005, there were no outstanding options or warrants to purchase shares of Common Stock which were excluded from the computation of the diluted earnings per share amount as the exercise prices of all outstanding options and warrants was less than the average market price of the shares of Common Stock.

NOTE 5 -- SEGMENT INFORMATION:

We follow the requirements contained in Statement of Financial Accounting Standards (SFAS) No.131, "Disclosures about Segments of an Enterprise and Related Information," with respect to identifying and reporting business segments. This statement requires that segment reporting reflect our organizational structure, major revenue sources, lines of responsibility and senior management's perspective of an organization. In order to better execute our business strategy and prepare for opportunities offered in the healthcare marketplace, we modified our reporting segments in 2005. We currently report two major lines of business, our Provider Services, which is comprised of our FertilityPartners and Affiliate segments, and our Consumer Services, which is comprised of our Shared Risk and Pharmaceutical segments.

9

INTEGRAMED AMERICA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED (unaudited)

		Providers Fertility		Consum Shared
	Corporate	Partners	Affiliates	Risk Pha
For the three months ended March 31, 2006				
Revenues	\$	\$27 , 497	\$ 279	\$2 , 505
Cost of Services		25,031	1	1,640
Contribution		2,466	278	 865
Operating Margin		9.0%	99.6%	34.5%
General and administrative	3,052			
Interest, net	(62)			
Income before income taxes	(2,990)	2,466	278	865
Depreciation expense included above	\$ 139	\$ 908	\$	\$
Capital expenditures	\$ 174	\$ 509	\$	\$
Total assets	\$22 , 783	\$41,219	\$ 90	\$ 523
For the three months ended March 31, 2005				
Revenues	\$	\$25,467	\$247	\$1,510
Cost of Services		22 , 967	52	1,060
Contribution		2,500	 195	450
Operating Margin		9.9%	78.9%	29.8%
General and administrative	2,834			
Interest, net	(3)			

Income before income taxes	(2,831)	2,500	195	450
Depreciation expense included above	\$ 92	\$ 853	\$	\$
Capital expenditures	\$ 264	\$ 1,814	\$	\$
Total assets	\$ 7 , 537	\$44,874	\$ 82	\$ 486
As of December 31, 2005				
Total assets	\$22,992	\$41,207	\$ 46	\$ 241

NOTE 6 - DUE TO MEDICAL PRACTICES

Due to Medical Practices is comprised of the net amounts owed by us to medical practices contracted as FertilityPartners. This balance is comprised of amounts due to us by the medical practices for funds, which we advanced for use in financing their accounts receivable, less balances owed to the medical practices by us for undistributed physician earnings and patient deposits we hold on behalf of the medical practices.

As of March 31, 2006 and December 31, 2005, Due to Medical Practices was comprised of the following balances:

	2005	2004
Advances to FertilityPartners Undistributed Physician Earnings Physician practice patient Deposits	\$(13,529) 2,534 14,979	\$(12,727) 3,721 13,955
Due to Medical Practices, net	\$ 3,984 =======	\$ 4,949 ======

10

INTEGRAMED AMERICA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED (unaudited)

NOTE 7 -- STOCK-BASED EMPLOYEE COMPENSATION:

As of March 31, 2006, we had two stock-based employee compensation plans, which are described more fully in Note 13 of the financial statements in our most recent Annual Report on Form 10-K.

In December 2004, the FASB issued SFAS No. 123 (revised 2004), "Share Based Payment" ("SFAS No. 123(R)"). SFAS No. 123(R) supersedes APB Opinion No. 25, "Accounting for Stock Issued to Employees". In 2005, we used APB Opinion No. 25 to account for the value of stock options granted to employees. Effective January 1, 2006, we adopted SFAS No. 123(R). In the first quarter of 2006, the adoption of SFAS No. 123(R) resulted in a charge to earnings of \$60,000 for the value of outstanding stock options issued in prior years. As of March, 31, 2006, we also had approximately \$27,000 of unrecognized compensation cost related to non-vested stock options which had been previously granted under our plans. That cost is expected to be recognized during the second quarter of 2006. This expected cost does not include the impact of any future stock-based compensation awards.

We also issue restricted stock grants to several officers and members of the Board of Directors. Stock granted to Board members vests immediately and stock granted to officers vests over a period of three years. Our General and Administrative expense includes compensation costs recognized in connection with these restricted stock grants of \$96,000 and \$84,000 for the three month periods ended March 31, 2006 and March 31, 2005 respectively.

NOTE 8 -- LITIGATION

From time to time, we are party to legal proceedings in the ordinary course of business. As of March 31, 2006, none of these proceedings is expected to have a material adverse effect on our financial position, results of operations or cash flow.

NOTE 9 -- RECENT ACCOUNTING STANDARDS

We disclose our critical accounting policies in our Form 10-K filled with the Securities and Exchange Commission. Since our most recent Form 10-K filling on December 31, 2005, none of those policies has changed, nor has any been added. At this time, there are no recently issued accounting standards which are expected to have a material impact on us.

11

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with the consolidated financial statements and notes thereto included in this quarterly report and with IntegraMed America Inc.'s Annual Report on Form 10-K for the year ended December 31, 2005.

Overview

IntegraMed America, Inc. offers products and services to patients and providers in the fertility industry. We have developed a network comprised of twenty-seven contracted fertility centers in major markets across the United States, products and services designed to support fertility center growth, products in the pharmaceutical and patient financing areas, and captive insurance offerings. Nineteen affiliate fertility centers purchase discrete service packages provided by us and have the right to distribute our consumer products, and eight fertility centers have access to our entire portfolio of products and services under our comprehensive FertilityPartners(TM) program. All twenty-seven centers have access to our consumer services, principally pharmaceutical products, and patient financing products.

The business strategy of our Provider Services segment is to leverage our deep expertise and commitment to improved fertility center performance by providing the best value-specific offerings and an overall long term relationship. The business strategy of our Consumer Segment is to provide products and services that make obtaining high quality care easier and more affordable. The primary elements of our strategy include: (i) expanding our network of fertility centers to the top 50 markets in the United States; (ii); (iii) increasing revenues and profits at contracted fertility centers;; and, (iv) increasing sales of pharmaceutical and treatment financing products to fertility patients.

Major events impacting financial condition and results of operations

In December 2005, we amended our existing credit agreement with Bank of America. The amended agreement is comprised of a renewal and increase in our

three-year revolving credit line to \$10 million, and a new \$10 million five-year term loan, of which approximately \$3.2 million was used to retire the outstanding balance on our previous term loan. We believe that these credit facilities will be sufficient to fund our current operational, capital investment and acquisition plans.

Through September 30, 2005, we marketed pharmaceutical products directly to patients throughout our network and we had contracted with ivpcare, inc. to provide certain business services related to the distribution of and accounting for these sales. Effective October 1, 2005, this agreement was terminated and replaced by a new agreement between us and ivpcare, inc. Under the terms of the new agreement, we are no longer a direct distributor of pharmaceutical products to patients, as this function is being performed directly by ivpcare. Our responsibilities are limited to marketing the products for which we will be compensated. This compensation will approximate our previous contribution from those pharmaceutical sales and services, and will be shown on a "net" rather than "gross" basis. As a result, as of October 1, 2005, we no longer record pharmaceutical sales, the related cost of sales and other costs related to pharmaceutical distribution. We anticipate significant decreases in revenues and cost of sales; however (assuming the same volume of pharmaceutical products is distributed) contribution from operations and income before income taxes, as well as net income, will be virtually unaffected by this contract change.

On May 23, 2005, the Company declared a 30% stock split effected in the form of a stock dividend for all holders of record as of June 8, 2005. As a result of this dividend, 1,129,141 new shares of the Company's common stock were issued on the payment date of June 22, 2005. No fractional shares were issued as all fractional amounts were rounded up to the next whole share. All weighted average shares outstanding and earnings per share calculations have been restated to reflect the stock split.

Effective January 1, 2005, we signed a FertilityPartners agreement to supply a complete range of business, marketing and facility services to the Reproductive Partners Medical Group, Inc. or RPMG, a fertility practice comprised of six physicians in the Southern California market. Under the terms of this 25-year agreement, our service fees are comprised of reimbursed costs of

12

services, a tiered percentage of revenues, and an additional fixed percentage of RPMG's earnings. We also committed up to \$0.5\$ million to fund any necessary capital needs of the practice.

Effective January 1, 2005, the Company became a minority equity investor in the Assisted Reproductive Technology Insurance Company, LTD, ("ARTIC"). ARTIC is incorporated as an off-shore captive insurance company designed to offer malpractice insurance to physicians and related facilities within the IntegraMed network. IntegraMed's equity investment of \$50,000 represents a 10% ownership stake, which is accounted for on the equity basis. The remaining equity of ARTIC is owned by participating physician groups. IntegraMed has agreed to provide certain administrative and risk management related services to ARTIC for a predetermined fee.

Results of Operations

The following table shows the percentage of net revenue represented by various expenses and other income items reflected in our statement of operations for the quarters ended March 31, 2006 and 2005:

For the three-month period ended March 31, _____ 2006 2005 Revenues, net: Provider services..... 91.3% Consumer services..... 8.7% 19.5% ____ ----Total revenues...... 100.0% 100.0% Costs of services incurred: 72.0% Provider services...... 82.2% 17.5% Consumer services..... 5.4% ____ ____ 87.6% 89.5% Total costs of service..... Contribution: 8.5% Consumer services..... 2.0% 3.3% 10.5% 8.9% General and administrative expenses........... 10.0% Interest income......(0.7)% (0.3)% Interest expense..... 0.5% 0.3% ____ ____ Total other expenses..... 9.8% 8.9% Income from operations before income taxes.... 2.6% 1.6% Income tax provision..... 1.0% 0.6% --------1.6% Net income 1.0%

Three Months Ended March 31, 2006 Compared to Three Months Ended March 31, 2005

Our revenues decreased by \$1.5 million, or 4.8%, to \$30.4 million for the three months ended March 31, 2006, as compared to \$32.0 million for the same period in 2005. The first quarter of 2005 included pharmaceutical distribution revenue of \$4.7 million, which due to a contract amendment as discussed above, reduced our pharmaceutical revenue but did not reduce our contribution from pharmaceutical sales. Other significant factors affecting our reported revenues were as follows:

13

(i) Provider Services -

Revenues from our Provider Services unit, comprised primarily of our FertilityPartners centers, Affiliate members and ARTIC services, increased by \$2.0 million, or 8.0% from the same quarter in the prior year. Approximately \$1.6 million of this increase was the result of internal growth within our eight FertilityPartner locations and is largely attributable to consumer marketing campaigns initiated in the fourth quarter of 2005.

Revenues from our Affiliate clinics increased approximately \$0.4

million in the first quarter of 2006 relative to the first quarter of 2005, reflecting both our growing network of affiliated fertility clinics, which increased from seventeen clinics as of March 31, 2005 to nineteen clinics as of March 31, 2006, and our ability to increase sales penetration at these clinics.

(ii) Consumer Services -

Our Shared Risk Refund program continued to see significant double-digit year-to-year growth with first quarter 2006 revenues of \$2.5 million, an increase of \$1.0 million, or 66%, above 2005 revenues of \$1.5 million for the same period. We believe that this program will show continued growth and are working to increase the acceptance and sales penetration of this product to targeted FertilityPartner and Affiliates locations within our network.

Pharmaceutical revenue was \$0.2 million for quarter ended March 31, 2006, compared to \$4.7 million for the same quarter in 2005. This reduction in revenue is primarily the result of a change in contract terms we initiated with our strategic partner in the pharmaceutical business, which became effective on October 1, 2005. Under the new contract terms, we no longer record the sales of pharmaceutical products as revenue and the cost of these products as costs of sales, but rather report net marketing fees associated with those sales. While these new terms do have an effect on our reported revenues, they will not have any impact on our net profit from those sales. As a result, reported revenues for 2006 are not directly comparable with 2005 results.

Contribution for the quarter ended March 31, 2006 of \$3.8 million increased approximately \$0.4 million, or 12.9%, from the same quarter in 2005. As a percentage of revenue, our contribution margin for the quarter increased to 12.4% in 2006 relative to 10.5% in 2005 due primarily to the current presentation of "net pharmaceutical revenue" as discussed above. The following factors had a significant impact on contribution:

(i) Provider Services -

Contribution from our FertilityPartners segment of \$2.5 million for the first quarter of 2006 was essentially even with the contribution in the prior year. Despite revenue growth of 8%, previously disclosed fee reductions at three FertilityPartners clinics reduced contribution growth. The year 2006 represents the final year of our multi-year fee realignment program. With the fee structures we currently have in place, we expect that continued revenue growth in future years will directly translate into growth in contribution.

Our Affiliate clinics generated contribution of \$0.3 million in 2006, an increase of \$0.1 million from their contribution in 2005. This increase is primarily the result of a net addition of two Affiliate clinics to our network since the first quarter of 2005.

(ii) Consumer Services -

Contribution from our Shared Risk Refund program rose by \$0.4 million, or 92%, to \$0.9 million for the quarter ended March 31, 2006, from \$0.5 million in 2005. This growth is attributable to increased patient volume and continued favorable pregnancy outcomes, especially during early treatment cycles.

14

Pharmaceutical contribution of \$0.2 million in 2006 was consistent with the contribution level in 2005. As previously stated, the change in contract terms with our strategic partner in the pharmaceutical business was designed to have no effect on our contribution from those underlying sales.

General and Administrative expenses are comprised of salaries, benefits, corporate regulatory, operational, administrative and support costs which are not specifically related to our clinical patient care or other product offerings. These costs were \$3.1 million in 2006, compared to \$2.8 million for the same period in 2005. Approximately \$0.1 million of this increase relates to wage and benefit items, with the remaining \$0.2 million representing an increase in general support and administrative costs.

Interest income increased to \$221,000 for the quarter ended March 31, 2006, from \$100,000 in 2004. This increase is primarily attributed to interest income earned on capital investments at several FertilityPartners clinics. Interest expense increased to \$159,000 for the first quarter of 2006, from \$97,000 in 2005, primarily as a result of interest charges on our existing bank debt, which is \$4.2 million higher than the balance outstanding in 2005.

Our provision for income tax was approximately 0.3 million in 2006, or 38.3% of pre-tax income, compared to 0.2 million, or 37.5% of pre-tax income in 2005, with the increase of 0.1 million resulting primarily from higher income levels in 2006 versus 2005. Our effective tax rates for both 2006 and 2005 reflect provisions for both state and federal income taxes.

Off-balance Sheet Arrangements

FASB Interpretation No. 46 (FIN 46R) "Consolidation of Variable Interest Entities" ("VIE's") addresses how a business enterprise should evaluate whether it has a controlling financial interest in an entity through means other than voting rights and accordingly should consolidate the entity. As part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or VIE's, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of March 31, 2006, we do not have an interest in any VIE's where we are the primary beneficiary, therefore the adoption of FIN 46 had no impact on our financial statements.

Liquidity and Capital Resources

As of March 31, 2006, we had approximately \$19.9 million in cash and cash equivalents on hand as compared to \$22.5 million at December 31, 2005. Additionally, we had working capital of approximately \$7.9 million, at March 31, 2006, an increase of \$1.2 million from working capital of \$6.7 million as of December 31, 2005. Our increased working capital is partially attributed to a reduction in accrued liabilities and reduced balances due to medical practices.

Shared Risk Refund patient deposits, which are reflected as a current liability, represent funds received from patients in advance of treatment cycles. These deposits, which represent prepayments of future revenues from patients without full insurance coverage, totaled approximately \$5.0 million and \$4.7 million as of March 31, 2006 and December 31, 2005, respectively. These deposits are a significant source of recurring cash flow and represent interest-free financing for us.

As of March 31, 2006, we did not have any significant contractual commitments for the acquisition of fixed assets or construction of leasehold improvements. However, we anticipate upcoming capital expenditures of approximately \$3.1 million for the remainder of 2006. These expenditures are primarily related to the expansion of our existing FertilityPartners centers. We believe that working capital, specifically cash and cash equivalents, remain at adequate levels to fund our operations and our commitments for fixed asset acquisitions. We also believe that the cash flows from our operations plus our available credit facility will be sufficient to provide for our future liquidity needs for the next twelve months.

15

In December 2005, we amended our existing credit facility with Bank of America. The amended facility is comprised of a \$10.0 million three-year revolving line of credit and a \$10.0 million 5-year term loan. As of March 31, 2006, approximately \$9.6 million of the term loan was outstanding with a remaining term of 4.75 years, and no balance was outstanding under the revolving line of credit.

Each component of this amended credit facility bears interest by reference to Bank of America's prime rate or LIBOR, at our option, plus a margin, which is dependent upon a leverage test, ranging from 1.75% to 2.50% in the case of LIBOR-based loans. Prime-based loans are made at Bank of America's prime rate and do not contain an additional margin. Interest on the prime-based loans is payable monthly and interest on LIBOR-based loans is payable on the last day of each applicable interest period. As of March 31, 2006, interest on both the term loan and revolving credit line were payable at a rate of approximately 6.36%. Unused amounts under the working capital revolver bear a commitment fee of 0.25% and are payable quarterly. Availability of borrowings under the working capital revolver is based on eligible accounts receivable, as defined in the credit agreement. As of March 31, 2006, under the revolving line of credit the full amount of \$10.0 million was available, of which none was outstanding. The Bank of America credit facility is collateralized by all of our assets. As of March 31, 2006, we were in full compliance with all applicable debt covenants.

We are also continuously reviewing our credit agreements and may renew, revise or enter into new agreements from time to time as deemed necessary.

Significant Contractual Obligations and Other Commercial Commitments:

The following summarizes our contractual obligations and other commercial commitments at March 31, 2006, and the effect such obligations are expected to have on our liquidity and cash flows in future periods.

Payments Due by Period

	Total	Less than 1 year	1 - 3 years	4 - 5 years
Notes Payable	\$ 9,643,000	\$1,428,000	\$ 2,858,000	\$ 5,357,000
Capital lease obligations	129,000	72,000	57,000	
Operating leases	47,204,000	6,509,000	10,901,000	8,944,000
FertilityPartners capital and				
other obligations	500,000	500,000		
Total contractual cash				
obligations	\$57,476,000	\$8,509,000	\$13,816,000	\$14,301,000

Amount of Commitment Expiration Per Period

	Total	Less than 1 year	1 - 3 years	4 - 5 years
Lines of credit	\$10,000,000	\$	\$10,000,000	\$

We also have commitments to provide working capital financing to our FertilityPartners locations. A significant portion of this commitment relates to our transactions with the medical practices themselves. Our responsibilities to the medical practices are to provide financing for their accounts receivable and to hold patient deposits on their behalf as well as undistributed physician earnings. Disbursements to the medical practices generally occur on or before the 20th business day of each month. The medical practice's repayment hierarchy consists of the following:

- (i) We provide a cash credit to the practice for billings to patients and insurance companies;
- (ii) We reduce the cash credit for clinic expenses that we have incurred on behalf of the practice;
- (iii) We reduce the cash credit for the base portion of our Service Fee which relates to the FertilityPartners revenues;

16

- (iv) We reduce the cash credit for the variable portion of our Service Fee which relates to the FertilityPartners earnings; and
- (v) We disburse to the medical practice the remaining cash amount which represents the physicians undistributed earnings.

We are also responsible for the collection of the FertilityPartners accounts receivables, which we finance with full recourse. We continuously fund these needs from our cash flow from operations, the collection of prior months' receivables and deposits from patients in advance of treatment. If delays in repayment are incurred, which have not as yet been encountered, we could draw on our existing working capital line of credit. We also make payments on behalf of the FertilityPartners for which we are reimbursed in the short-term. Other than these payments, as a general course, we do not make other advances to the medical practice. We have no other funding commitments to the FertilityPartners.

New Accounting Pronouncements

At this time, there are no recently issued accounting standards which are expected to have a material impact on us.

Forward Looking Statements

This Form 10-Q and discussions and/or announcements made by or on behalf of us, contain certain forward-looking statements regarding events and/or anticipated results within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, the attainment of which involves various risks and uncertainties. Forward-looking statements may be identified by the use of forward-looking terminology such as, "may", "will", "expect", "believe", "estimate", "anticipate", "continue", or similar terms, variations of those terms or the negative of those terms. Our actual results may differ materially from those described in these forward-looking statements due

to the following factors: our ability to acquire additional FertilityPartners agreements, our ability to raise additional debt and/or equity capital to finance future growth, the loss of significant FertilityPartners agreement(s), the profitability or lack thereof at fertility centers serviced by us, increases in overhead due to expansion, the exclusion of fertility and ART services from insurance coverage, government laws and regulation regarding health care, changes in managed care contracting, the timely development of and acceptance of new fertility, and ART and/or genetic technologies and techniques. We are under no obligation to (and expressly disclaim any such obligation) update or alter any forward-looking statements whether as a result of new information, future events or otherwise.

17

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our interest income and expense items are sensitive to changes in the general level of interest rates. At March 31, 2006 we had an outstanding balance of approximately \$9.7 million on our term loan. This borrowing has a remaining term of 4.75 years, and bears interest at either the Prime Rate, or at LIBOR plus a margin. As of March 31, 2006, this borrowing had an interest rate of approximately 6.36%. We also receive interest income from short-term investments and certain advances to FertilityPartner clinics, both of which are tied to the Prime Rate. As of March 31, 2006, a one percent change in interest rates would impact our pre-tax and net income by less than \$10,000. As of March 31, 2006, we have not entered into any interest rate swap transactions.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15 under the Exchange Act) as of March 31, 2006 (the "Evaluation Date"). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the Evaluation Date, our disclosure controls and procedures were effective in timely alerting them to the material information relating to us required to be included in our periodic SEC filings.

Section 404 of the Sarbanes-Oxley Act requires us to provide an assessment of the effectiveness of our internal control over financial reporting as of the end of fiscal year 2007. We are in the process of performing the system and process documentation, evaluation and testing necessary to make its assessment. We have not completed this process or its assessment. In the process of evaluation and testing, we may identify deficiencies that will require remediation.

(b) Changes in internal controls.

As of the end of the period covered by our restated Form 10-K, we identified and disclosed two material weaknesses in our internal control over financial reporting. A weakness at a FertilityPartner location was comprised of a lack of sufficient oversight over, and the proper segregation of, duties with

respect to the processes of initiating, authorizing, recording and processing certain period end closing transactions, as well as the design effectiveness of related fraud detection controls. To remediate this material weakness, we have made certain personnel changes, changes in assigned roles and responsibilities, and changes in procedures and processes for certain transactions. The other weakness relates to not properly accounting for the deferred income tax aspects of acquiring the stock of Reproductive Partners, Inc., in January 2005. To remediate this weakness we have taken steps to supplement our existing staff with external expertise in tax accounting and disclosure.

Other than these changes, there were no significant changes made in our internal controls during the period covered by this report or, to our knowledge, in other factors that could significantly affect these controls subsequent to the date of their evaluation.

18

Part II - OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we are party to legal proceedings in the ordinary course of business. As of March 31, 2006, none of these proceedings is expected to have a material adverse effect on our financial position, results of operations or cash flow.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

- Item 3. Defaults Upon Senior Securities.
 None.
- Item 4. Submission of Matters to Vote of Security Holders.
- Item 5. Other Information.
 None.
- Item 6. Exhibits.

See Index to Exhibits on Page 21.

19

SIGNATURES

the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INTEGRAMED AMERICA, INC.
(Registrant)

Date: December 27, 2006 By: /s/:John W. Hlywak, Jr.

John W. Hlywak, Jr.
Executive Vice President and
Chief Financial Officer
(Principal Financial and
Accounting Officer)

20

INDEX TO EXHIBITS

Exhibit Number	Exhibit
3.2(d)	 Copy of By-laws of Registrant (as Amended on March 6, 2006) filed as exhibit with identical exhibit number to Registrant's Report on Form 10-Q for the period ended March 31, 2006.
31.1	 CEO Certification Pursuant to 18 U.S.C. ss. 1350 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated December 27, 2006.
31.2	 CFO Certification Pursuant to 18 U.S.C. ss. 1350 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated December 27, 2006.
32.1	 CEO Certification Pursuant to 18 U.S.C. ss. 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 dated December 27, 2006.
32.2	 CFO Certification Pursuant to 18 U.S.C. ss. 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 dated December 27, 2006.